Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen

Didu Kariyawasam 1,2 Arlene D’Silva,2 James Howells,3 Karen Herbert,4 Peter Geelan-Small,5 Cindy Shin-Yi Lin,3 Michelle Anne Farrar 1,2

ABSTRACT

Objectives: To elucidate the motor unit response to intrathecal nusinersen in children with symptomatic spinal muscular atrophy (SMA) using a novel motor unit number estimation technique.

Methods: MScanFit MUNE studies were sequentially undertaken from the abductor pollicis brevis muscle after stimulation of the median nerve in a prospective cohort of symptomatic children with SMA, undergoing intrathecal treatment with nusinersen at a single neuromuscular centre from June 2017 to August 2019. Electrophysiological measures included compound muscle action potential (CMAP), motor unit number estimation (MUNE), motor unit number contributing to 50%–100% of CMAP (N50) and measures of collateral reinnervation including largest single motor unit potential (LSMUP) and amplitude of the smallest unit contributing to N50 (AS50).

Results: Twenty children (median age 99 months, range 4–193) were followed for a median of 13.8 (4–33.5) months. Therapeutic intervention was an independent and significant contributor to an increase in CMAP (p = 0.005), MUNE (p = 0.001) and N50 (p = 0.04). The magnitude of this electrophysiological response was increased in children with shorter disease durations (p<0.05). Electrophysiological changes delineated children who were functionally stable from those who attained clinically significant gains in motor function.

Interpretation: Nusinersen therapy facilitated functional innervation in SMA through recovery of smaller motor units. Delineation of biomechanisms of therapeutic response may be the first step in identifying potential novel targets for disease modification in this and other motor neuropathies. MScanFit MUNE techniques may have a broader role in establishing biomarkers of therapeutic response in similar adult-onset diseases.

INTRODUCTION

Spinal muscular atrophy (SMA) is a rare genetic disease with a wide phenotypic spectrum.1 Disease pathophysiology centres around irreversible loss of motor neurons in the spinal cord and brainstem.2 Deficiency of survival motor neuron (SMN) protein secondary to homozygous disruption of survival motor neuron 1 gene (SMN1) forms the aetiological basis of disease.3 A paralogous gene, survival motor neuron 2 (SMN2) produces a small quantity of functional protein, varying in copy number to ameliorate phenotype in a dose-dependent manner.4

The advent of nusinersen, the first disease-modifying therapy, heralded a new treatment era for this condition acting as an SMN2 enhancer to increase SMN protein levels.4 With therapeutic intervention, improvements in survival and attainment of motor skills are noted in comparison to historical controls.5 In contrast to this well-documented clinical response, the physiological effects of SMN repletion at the motor unit level have not been elucidated in affected patients. This lack of biomechanistic knowledge is a rate limiting factor for development of therapeutic biomarkers6 and the evolution of therapeutics that may harness the motor unit’s ability to remodel, both of which impede the optimisation of clinical outcomes for affected individuals.7

Electrophysiological biomarkers of denervation were first developed to track motor neuron loss in adult-onset motor neuropathies,8 acting as indicators for treatment acceleration, modification and to define treatment limits.9 Similar potential exists in paediatric-onset conditions such as SMA. Accordingly, clinical trials for SMA have started to incorporate and track treatment-associated compound muscle action potential (CMAP) changes. Stabilisation and/or improvement of CMAP in symptomatic infants and in later-onset forms of the disease after therapeutic intervention are observed.10,11 However, this single measure is not sensitive enough to quantify subtle changes in denervation, with preserved values noted despite 50% loss of the motor neuron pool.12 Instead, electrophysiological measures such as motor unit number estimation (MUNE) and single motor unit amplitude (SMUP) more accurately reflect the health of the motor neuron pool, delineating flux in denervation (signified by MUNE) and collateral reinnervation (signified by SMUP) capacity of motor units.

Muscle Scans and the associated MUNE estimation (MScanFit) provide a novel method for motor unit number estimation, eliminating sources of error in traditional techniques.13 While this method is a sensitive and specific way of monitoring early disease progression in adult neuropathies,13 its utility in defining disease status is only now being recognised in treatment-naïve children with SMA.14 Its role in treated cohorts has not previously been investigated.

Accordingly, this is the first study to investigate the utility of five Muscle Scan parameters to define the basis, timing and extent of motor unit changes with SMN repletion therapy, in a prospectively
studied cohort of children with SMA. This study uniquely investigates clinical measures that predict an electrophysiological response, exploring the interplay between denervation and reinnervation across a spectrum of clinical phenotypes, shedding light on the therapeutic window and clinical confounders that modulate response.

METHODS

Study design

This was a single centre prospective cross-sectional and longitudinal study measuring clinical, functional and electrophysiological outcomes in infants, children and adolescents with SMA conducted between June 2017 and October 2019. Inclusion and exclusion criteria are detailed in table 1.

Study measures

Clinical measures

Demographic and medical data, as detailed in table 2, were collated from electronic medical records. ‘Current’ functional motor status is a useful and pragmatic way of classifying children with SMA and has been used to functionally define children with SMA in international standard of care consensus guidelines. Our participants were similarly stratified as (non-sitter, sitter and walker) against WHO developmental milestones at 1 month prior to therapeutic intervention and 1 month after study completion. Classification of SMA phenotype for this study adhered to guidelines set out in the International Collaborative SMA Workshop.

Functional motor assessments

Validated assessments for use in children with SMA include the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND), for weak infants or children <2 years of age, and Hammersmith Functional Motor Scale/extended version (HFMS/E) for older individuals and/or in those who have demonstrated at minimum, the ability to sit. In both assessments, higher scores indicate better motor function. Baseline and final assessments were completed within a month of commencing therapy and completing the study, respectively. Assessments were administered and scored by a senior neuromuscular physiotherapist (KH), trained in using validated SMA motor scores. Clinically significant motor improvement or deterioration was defined as ≥4-point increase or decrease.

Table 1  Study inclusion and exclusion criteria for participants in the study

| Inclusion criteria                                      | Exclusion criteria                                                                 |
|---------------------------------------------------------|-----------------------------------------------------------------------------------|
| Genetically confirmed homozygous SMN1 deletions         | Children who were beyond >4 months since commencement of treatment, that is, those who had already transitioned to nusinersen maintenance treatment at the start of the study |
| Clinical signs and symptoms consistent with a diagnosis of SMA | Children with comorbidities or medication use potentially associated with development of peripheral neuropathy or neuromuscular disease |
| Age 4 months–20 years                                  | Serious illnesses/comorbidities that would affect clinical or electrophysiological assessment in the view of the researchers |
| Functional status (non-sitter, sitter, walker)          | Children who did not tolerate or were unwilling to undertake sequential studies |
| Receiving intrathecal nusinersen as part of clinical management at Sydney Children's Hospital New South Wales, Australia | Children who were treated with a disease-modifying agent other than nusinersen |

Written informed, voluntary consent given by parent/legal guardian or young person according to the principles set out in the Declaration of Helsinki:

1. By parents for children <6 years.
2. Parents and child for children 7–17 years old.
3. Young person if >18 years of age.

Non-English speakers were consented with the aid of an interpreter.

Sex and SMN2 copy number of participants in each SMA phenotypic subgroup and for the total cohort are expressed as n (%). SMA, spinal muscular atrophy.

Table 2  Clinical characteristics of participants in each SMA phenotypic subgroup and for the total cohort

| Characteristics                   | SMA type 1, N=6 | SMA type 2, N=10 | SMA type 3, N=4 | Total, N=20 |
|-----------------------------------|-----------------|-----------------|----------------|------------|
| Sex                               |                 |                 |                |            |
| Male                              | 2 (33%)         | 6 (60%)         | 3 (75%)        | 11 (55%)   |
| Female                            | 4 (66%)         | 4 (40%)         | 1 (25%)        | 9 (45%)    |
| SMN2 copy number                  |                 |                 |                |            |
| 2                                 | 1 (17%)         | 1 (11%)         | 1 (25%)        | 3 (16%)    |
| 3                                 | 5 (83%)         | 8 (89%)         | 3 (75%)        | 16 (84%)   |
| Age at symptom onset (months)     |                 |                 |                |            |
| Median, (range), SD               | 3.5, (2–5), 1.11| 12, (8–18), 7.8 | 22.5, (18.5–144), 65.2 | 12, (2–144), 30.5 |
| Age at time of study (months)     |                 |                 |                |            |
| Median, (range), SD               | 11.5, (4–178), 67.7 | 99, (13–153), 42 | 127.5, (109–193), 37.2 | 99, (4–193), 59.3 |
| Disease duration (months)         |                 |                 |                |            |
| Median, (range), SD               | 7.2, (2–175), 68.2 | 77, (1–141), 41.7 | 104.5, (52–114), 29 | 63 (2–175), 51.6 |
| Duration of study follow-up (months) | 26.8, (21.5–33.5), 5.0 | 12.8, (4–26), 5.9 | 12, (6–14), 3.8 | 13.8 (4–33.5), 8.6 |

Classification of SMA phenotype for this study adhered to guidelines set out in the International Collaborative SMA Workshop. SMA type 1 (symptom onset <6 months, unable to sit independently), SMA type 2 (symptom onset 7–18 months, sits independently) and SMA type 3 (symptom onset >18 months of age, walks independently at time of diagnosis).

Age at the time of study, age at symptom onset, disease duration (interval between age of symptom onset and age at first nusinersen treatment) and study follow-up duration are expressed as median, (range), standard deviation (months).

Sex and SMN2 copy number of participants in each SMA phenotypic subgroup and for the total cohort are expressed as n (%).

*Nineteen out of 20 (95%) of children had SMN2 copy number available (missing data for a child with SMA type 2 phenotype).

SMA, spinal muscular atrophy.

Kariyawasam D, et al. J Neurol Neurosurg Psychiatry 2021;92:78–85. doi:10.1136/jnnp-2020-324254
Electrophysiological measures obtained using MScanFit MUNE

The protocol established by Jacobsen et al. was used to estimate the number of motor units of the abductor pollicis brevis (APB) muscle, innervated by the median nerve. The same APB muscle was sequentially tested in each individual.

Each participant’s hand and forearm were cleansed with NuPrep abrasive skin prepping gel (Weaver and Company, Aurora, USA). ECG-type non-polarisable Ag/AgCl surface electrodes (4620M; Unomedical, Birkerød, Denmark) were used for recording with the active electrode placed over the APB muscle belly and the reference electrode placed distally over the tendon insertion at the metacarpophalangeal joint of the thumb. Ground electrodes were placed on the dorsum and palm of the hand. The optimal stimulation site of the median nerve was located at the wrist by identifying the largest electromyograph (EMG) response to a submaximal stimulus, using repositionable bipolar electrodes, before fixing stimulating electrodes (the same as used for recording). Movement of the thumb was limited by taping the digit to a supporting surface.

Stimulation of the median nerve was coordinated by QtracS software (H. Bostock, Institute of Neurology, University College London, UK) with the TRONDNF protocol, using a data acquisition system (PCI-6221; National Instruments, Austin, Texas, USA). The data acquisition system provided the command signals for a constant-current simulator (DS5, Digitimer, Welwyn Garden City, UK). Measurements were amplified and filtered using a purpose built low noise (amplifier gain × 250; Amplinstruments, Welwyn Garden City, UK). Measurements were amplified and signals for a constant-current simulator (DS5, Digitimer, Welwyn Garden City, UK) were used for recording with the active electrode placed over the APB muscle belly and the reference electrode placed distally over the tendon insertion at the metacarpophalangeal joint of the thumb. Ground electrodes were placed on the dorsum and palm of the hand. The optimal stimulation site of the median nerve was located at the wrist by identifying the largest electromyograph (EMG) response to a submaximal stimulus, using repositionable bipolar electrodes, before fixing stimulating electrodes (the same as used for recording). Movement of the thumb was limited by taping the digit to a supporting surface.

Statistical analysis

Statistical modelling was performed in R statistical software, V3.6.2 (R Core Team (2019)). Throughout statistical analysis, normal quantile–quantile plots of residuals demonstrated no gross deviations from the normal distribution; residual versus fitted value plots indicated non-uniform variance, which was stabilised by log-transforming outcome variables. For cross-sectional data (at the start of therapy), one-way analysis of variance was used to ascertain differences in electrophysiological values between SMA phenotypes, WHO-derived functional motor status and SMN2 copy number at start of therapy. The Pearson’s correlation coefficient test was used to determine the relationship between baseline electrophysiological values and motor function at start of therapy as assessed on validated SMA functional motor scales. For analysis of the longitudinal data, continuous responses were modelled with a linear mixed model, as there were multiple measurements per patient. Each electrophysiological outcome variable was modelled with explanatory variables. SMA phenotype, functional motor status at start of therapy, SMN2 copy number, disease duration and age of first intervention were all included in the model. Model selections for models with and without interactions were performed using the conditional Akaike information criterion (AIC), owing to the small size of this data set. The AIC enables model selection by estimating the quality of a selected model relative to other candidate models for a given data set. Fitted means and 95% CI were obtained and back-transformed values reported. A p value of <0.05 was considered significant. A binary logistic regression model to the recorded scan. In addition to maximal CMAP, optimisations to reduce differences and improve the fit of the model to the recorded scan. In addition to maximal CMAP, which is a broad measure of neuromuscular health, the following Muscle Scan measures were derived:

1. MUNE: the estimated number of functional motor units.
2. N50: the estimated number of larger units making up 50%–100% of the amplitude of CMAP (figure 1).
model was used to assess change in motor function with treatment (on validated SMA motor scales) against each electrophysiological variable, and fitted probabilities with CIs were obtained.

RESULTS
Clinical characteristics
The study population of 20 participants included 11 male and nine female (table 2). Children were Classification of SMA phenotype for this study adhered to guidelines set out in the International Collaborative SMA Workshop. Functionally, prior to the start of treatment, 5 children (25%) were classified as non-sitters, 13 (65%) as sitters and 2 children (10%) walked either independently or with support.

Electrophysiological measures
Due to the nature of embedding this research into the course of clinical management, the interval between and total number of studies varied among individuals. The mean recording time for each test was 3.4 min, SD 1.4 min. All tests were well tolerated by participants with no need for extraneous sedation/anaesthetic. No side effects were observed from the technique. ICC test of reliability for MUNE and CMAP showed good reliability for all measures. ICC for MUNE was 0.95 (p=0.02) and for CMAP was 0.98 (p=0.002).

Electrophysiological measures and their association with clinical measures of disease severity prior to therapy
There were significant differences in mean CMAP (p=0.03), MUNE (p=0.01) and N50 (p=0.01) between children with different SMA phenotypes, where children with SMA type 3 had the highest number of functional motor units and CMAP values at the start of therapy (figure 2A). Children across the spectrum of SMA phenotypes exhibited large motor units as suggested by the fact that no significant differences between LSMUP (p=0.30) and A50 (p=0.6) existed between phenotypes. There were significant differences in mean values for CMAP (p=0.003), MUNE (p<0.001) and N50 (p=0.001) between functional groups (as derived by WHO motor status at start of therapy). Children who had better functional motor skills (such as ambulatory ability) prior to therapeutic intervention showed lower levels of denervation represented by higher mean CMAP, MUNE and N50 values (figure 2B). Levels of collateral reinnervation were not significantly different among functional subgroups as denoted by LSMUP (p=0.09) and A50 (p=0.3). There were no significant differences in electrophysiological measures between children with different SMN2 copy numbers (CMAP p=0.34; MUNE p=0.22; N50 p=0.24; LSMUP p=0.54 and A50 p=0.18).

Longitudinal changes in electrophysiological measures with therapeutic intervention
Therapeutic intervention with nusinersen was an independent and significant contributor to an increase in CMAP (p=0.005), MUNE (p=0.001) and N50 (p=0.04). The extent of compensatory collateral reinnervation did not change with therapy (LSMUP p=0.99 and A50 p=0.77)). In contrast, a greater number of smaller units increasingly contributed to the overall CMAP as denoted by increasing differences between MUNE and N50 values. A representative example of electrophysiological changes with treatment from our cohort is shown in figure 3. During the first 2 months of therapy, there were no significant changes in any electrophysiological outcome measure (figure 4). MUNE was the initial electrophysiological measure to show a significant response, with increases noted after 6 months of treatment, (p=0.02), continuing without plateau for the duration of the study (figure 4). Concomitantly, a significant increase in CMAP was observed between the start and 18 months of therapy (p=0.001). The largest single motor unit potential did not change significantly over the therapeutic course (p=0.99).
Clinical factors and their effects on the magnitude of electrophysiological response with treatment

Disease duration and therapeutic intervention in combination significantly modified MUNE (p=0.003), CMAP (p=0.04) and N50 (p=0.03) over time. Changes in MUNE secondary to therapeutic intervention, negatively correlated with disease duration. A decrease of MUNE (7%), CMAP (6%) and N50 (8%), respectively, was observed for every six additional months of disease duration. This clinical factor had no impact on LSMUP (p=0.06) or A50 (p=0.07) over time.

Age of intervention and therapeutic intervention in combination significantly modified the electrophysiological response to therapy MUNE (p=0.001) and N50 (p=0.004). MUNE and N50 values correlated positively, with a rise of 7% and 7.5%, respectively, for every six additional months of age at intervention.

SMA phenotype, SMN2 copy number and gross functional status (as derived by WHO assessment) at the start of therapy did not have a significant association with electrophysiological measures seen over the study period (p>0.05).

Electrophysiological measures and their association with change in motor function

Out of the cohort who underwent longitudinal electrophysiological studies, two patients, both categorised with SMA type III, did not tolerate functional assessment at the end of the study period. Of the 18 children who completed functional motor assessments, the majority remained clinically stable (n=12, 67%) or showed clinically significant improvements (as validated by change in the HFMS/E/CHOP-INTEND scores) in motor scores (n=6, 33%). There was a trend towards an association between increasing CMAP, MUNE and N50 values and probability of (previously defined) clinically significant improvement on validated SMA motor scales. Although none of the children in our cohort demonstrated a magnitude of electrophysiological change large enough to confirm the significance of this trend (MUNE p=0.34), (CMAP p=0.69) and (N50 p=0.35), our analysis predicted that children with an increase in CMAP≥4.5 mV or an increase in MUNE≥15 units from baseline were more likely to attain significant improvements in motor function on validated SMA scales, with treatment. Children who had an increase in N50 of ≥4 units were more likely to have a clinically significant improvement in motor function with treatment, than be classified as clinically stable.

INTERPRETATION

This study describes the pathophysiologica status of the motor unit prior to therapeutic intervention in children with symptomatic SMA, the biophysical responses to SMN repletion, detailing the limits of the ‘therapeutic window’ and characteristics of the ‘therapeutic cohort’. Our study is the first to show that commencement of antisense oligonucleotide therapy halts disease-related axonal loss, altering the established degenerative electrophysiological trajectory in untreated children.

This study uniquely denotes that motor unit number increases soon after therapeutic induction. Biological effects continue throughout maintenance with preferential restoration of small motor units to functionality. Electrophysiological measures correlate with functional change, highlighting the capacity of MUNE measures to act as biomarkers of therapeutic response. Our findings form the foundation for the goal of precision medicine and may, in the future, have broader utility in tracking treatment response in adult-onset motor neuropathy.

Prior to treatment, children who have a higher burden of disease (characterised by SMA phenotype and/or lower functional motor status), have lower CMAP, MUNE and N50, reflecting comparatively higher levels of neuronal degeneration. Our findings mirror natural history studies showing increased levels of motor neuron loss in children with an SMA type 1 phenotype, compared with those with later and milder onset disease, while adding knowledge by suggesting similar associations between neuronal loss and motor function.

Our study finds that disease severity in SMA appears more closely associated with the extent of denervation, with surviving motor units across SMA phenotypes and functional groups similarly mechanistically compensated, with comparative LSMUP and A50 values. This has been demonstrated in natural history studies where a threefold increase in motor unit size appeared functionally inadequate to compensate for a 90% disease-related reduction in motor unit number.

The present study demonstrates the differing electrophysiological trajectory in treated, symptomatic children compared with historically untreated counterparts. In the latter, early and precipitous motor unit number and corresponding CMAP decline is the main mechanism of disease. In contrast, at a biological level, our study suggests that nusinersen leads to cessation of disease-related denervation, remodels the motor unit pool, and is hence a true disease-modifying agent.

In contrast to other (infectious and demyelinating) motor neuropathies that show an increasing degree of collateral reinnervation as the major contributor to CMAP restoration during illness recovery, we observe that axonal sprouting has less of a mechanistic role to play in the therapeutic response. This is possibly due to motor unit size being maximally compensated in the process of chronic denervation, as has been electrophysiologically captured in SMA and other neuropathic disease processes such as poliomyelitis.

Although small and large units simultaneously recover with intervention, smaller, units recover first and preferentially, denoted by a more significant rise in MUNE (total number of functional motor units) compared with N50 (number of larger...
motor units. Our study is the first to replicate in a clinical cohort, preclinical models of SMN repletion and increased resilience of small motor units.

Our findings corroborate clinical trial data demonstrating increase and maintenance of CMAP in treated children with infantile onset disease (known as CMAP responders) compared with untreated patients. In contrast to outcomes from clinical trials in later-onset forms of SMA showing only small increments or decrements in CMAP and/or MUNE in children with SMA type 2 and 3 respectively, this electrophysiological response is noted across the spectrum of our heterogeneous cohort, independently of other clinical factors. Discrepancies in observations between studies may be due to the motor unit number estimation technique, measurement of median nerve pathology (ulnar nerve was tested in the clinical trial) and variation in baseline demographics.

Nusinersen exerts its biological effect early on. Motor unit number improves soon after the first 2 months of therapy, consistent with preclinical literature showing termination of motor neuron loss in the first phases of SMN restoration. An increase in functional motor unit number continues (>18 months) without reaching a plateau phase, mirroring outcomes from clinical trials that shows ongoing motor gains over the first 2 years of therapy. Our findings may indicate that premature cessation of intervention due to lack of functional benefit could interrupt an ongoing motor unit innervation process, which leads to clinical benefit in the longer term.

Our study gives rise to several hypotheses surrounding the mechanism of motor unit number restoration with treatment. Although MScan Fit MUNE takes into account threshold variability of all functional motor units and is a sensitive measure of motor neuron loss in adult diseases, challenges remain (as with all MUNE techniques) in detecting the smallest motor units with a non-invasive methodology. With treatment, these very small motor units may enlarge in size and are captured as they surpass the threshold for detection.

Axonal regeneration has been observed in acute and chronic peripheral neuropathies when environmental insults are withdrawn and may represent a distinct biomechanistic pathway for motor unit number restoration. However, structural reinnervation has not previously been described in preclinical models of SMN repletion and chronic denervation leading to chronic axotomisation, as seen in SMA is known to especially inhibit axonal regeneration.

A return of function to pre-existing ‘dysfunctional’ axons possibly at the cusps of degeneration is another postulated process by which chronically denervated motor units respond to SMN2 enhancing therapies. Our findings may support emerging biological concepts of reversible pathophysiology in affected neurons including restoration of neuromuscular junction function, improved synaptic and neuronal cell trafficking, and/or reversal of axonal conduction block, with commencement of therapy.

One further potential interpretation of our data is that an increase in motor unit number is secondary to a developmental phenomenon; however, prior (limited) data for healthy young subjects show that motor unit number appears stable from the neonatal period to adulthood. Furthermore, SMA has an established natural history of denervation, such that developmental phenomenon would not be expected in a longitudinal study in patients with SMA. Preclinical models suggest that SMA is a developmental as well as neurodegenerative pathology. An ‘unlocking’ and restoration of halted, disease-related neuronal development after repletion of SMN levels may underpin our electrophysiological findings. Future studies using MScan Fit MUNE methodology in age-sex matched healthy children are required to delineate this further. Excitability studies exploring biophysical properties of the motor unit in symptomatic and healthy controls may also provide a more in-depth understanding of the biomechanisms behind our results.

Clinical factors that predict treatment response on a neurophysiological level relate strongly to disease duration and age of intervention. Traditional clinical determinants of disease severity such as phenotype and SMN2 copy number do not modulate electrophysiological sequelae significantly.

Children with a longer symptomatic phase of disease have a reduced capacity to increase their functional motor unit number with treatment. The electrophysiological sequelae mirror outcomes across clinical trial and real-world settings that observe greater improvements in survival and motor outcomes in patients who are treated earlier in their disease course. Our findings contribute to the expanding clinical evidence base that promotes early (and potentially presymptomatic) intervention with disease-modifying agents to halt and potentially reverse rapid disease-associated motor neuron loss.

Clinical trial outcomes show clear benefit of therapy in young children with severe forms of SMA with less clear cut outcomes associated with other SMA phenotypes. Our study has demonstrated that the ‘therapeutic cohort’ is more heterogeneous than originally anticipated; children who are beyond the age of expected developmental gains (ie, older children/adolescents and young adults who are still ambulant) maintain a significant capacity for functional motor unit innervation with therapy and may accrue clinical benefit from nusinersen therapy. Thus, the therapeutic window is such that a broad range of patients will benefit from therapy, with patient-reported outcomes emphasising that stability is important, in the context of a neurodegenerative disease. Our findings emphasise the need to provide active intervention with allied therapy to preserve joint range, nutritional status and muscle mass as a standard of care among symptomatic children, so that the biological potential of these therapeutics can be fully harnessed.

The present study starts to explore electrophysiological parameters as biomarkers of disease severity and treatment response. Our findings propose that change in CMAP, MUNE and N50 have potential to predict individuals who are functionally stable, from those who attain clinically significant gains in motor function, with treatment. This parallels strong correlations observed between improving functional motor scales and rising CMAP values after intervention with disease-modifying agents in SMA. MScanFit MUNE studies may be similarly useful in categorising disease severity and therapeutic response in adult-onset motor neuropathies, including in adult-onset SMA.

The development and utility of biomarkers of disease severity and treatment response in a paediatric population are limited by concerns surrounding safety, tolerability and replicability of methods used to obtain these measures. Our study suggests that MScan Fit MUNE overcomes many of these barriers; the methodology is non-invasive, feasible, reproducible, tolerated (no child required extraneous sedation to complete the study) and quick to administer in children in a real-world setting. Although still considered a research tool, our study suggests that this automated technique may be adopted at the bedside to individualise treatment regimens for children with SMA. Future clinical trials incorporating MScanFit MUNE as an exploratory outcome utilising larger symptomatic cohorts and longer term follow-up are warranted to assess the wider applicability of this methodology.

Kariyawasam D, et al. J Neurol Neurosurg Psychiatry 2021;92:78–85. doi:10.1136/jnnp-2020-324254

83 Neuromuscular
Although classically thought of as a disease of proximal muscles, distal muscles are also severely affected across the phenotypic spectrum in SMA and have been the preferred target of investigation in clinical trials in SMA. We chose to study the APB muscle due to its accessibility in paediatric patients, and its importance as the most intact and clinically important distal muscle (for preservation of hand function) in children with SMA. The response to therapeutic intervention in other muscle groups requires further evaluation.

Our study used motor scales that have been validated as functionally meaningful for children with SMA. There is a paucity of (clinically meaningful), upper-limb-specific functional scales and strength measures that can be feasibly used and standardised across heterogeneous populations as seen in our cohort. The concurrent development of scales that are deemed functionally important and that meet the needs of a real-world population is necessary to fully interrogate the role of electrophysiological measures as clinically meaningful biomarkers of treatment response.

REFERENCES

1. Awano T, Kim J-K, Monani UR. Spinal muscular atrophy: journeying from bench to bedside. Neurotherapeutics 2014;11:786–95.
2. Dubowitz V. Ramblings in the history of spinal muscular atrophy. Neuromuscul Disord 2009;19:69–73.
3. Lefebvre S, Bürglen L, Reboutet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995;80:155–65.
4. Wunster CD, Ludolph AC. Antisense oligonucleotides in neurological disorders. Ther Adv Neurol Disord 2018;11:175628411778632.
5. Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med 2018;378:625–35.
6. Kariyawasam DST, D'Silva A, Lin C, et al. Biomarkers and the development of a personalized medicine approach in spinal muscular atrophy. Front Neurol 2019;10:898.
38 Gawel M, Koster-Pruszczyk A, Lusakowska A, et al. Motor unit loss estimation by the multipoint incremental MUNE method in children with spinal muscular atrophy—\textit{a preliminary study}. \textit{Neuromuscul Disord} 2015;25:216–21.

39 Vrbova G, Slawinska U. Critical period of neuromuscular development: importance for a new treatment of SMA. \textit{Neuromuscul Disord} 2018;28:385–93.

40 Bromberg MB, Swoboda KJ. Motor unit number estimation in infants and children with spinal muscular atrophy. \textit{Muscle Nerve} 2002;25:445–7.

41 Günther R, Neuwirth C, Koch JC, et al. Motor unit number index (MUNIX) of hand muscles is a disease biomarker for adult spinal muscular atrophy. \textit{Clin Neurophysiol} 2019;130:315–9.